PARAGON-HF - considerations for potential use of sacubitril-valsartan in real-world heart failure with mildly reduced ejection fraction

Recently, the results of the much anticipated Prospective Comparison of ARNI [angiotensin receptor –neprilysin inhibitor] with ARB [angiotensin-receptor blockers] Global Outcomes in HF with Preserved Ejection Fraction (PARAGON-HF) trial were published,1 showing that in patients with HFpEF (symptomatic HF, left ventricular EF ≥45%, structural heart disease, and elevated natriuretic peptides), sacubitril/valsartan compared to valsartan did not significantly improve the primary outcome of cardiovascular death or total HF hospitalizations (rate ratio 0.87; 95% confidence interval 0.75-1.01; p=0.06).

Source: Journal of Cardiac Failure - November 30, 2019 Category: Cardiology Authors: Lars H. Lund, Gianluigi Savarese Tags: Editorial Comment Source Type: research